The notices it replaced
- Reissues: PAR-18-684 NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R33 Clinical Trial Required)
Replaced by PAR-24-172.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,396,345 in first-year total cost, median $881,207.
Most frequent study sections
- Special Emphasis Panel[ZHL1 CSR-B (F4)]1
- Special Emphasis Panel[ZHL1 CSR-H (F1)]1
- Special Emphasis Panel[ZHL1 CSR-Z (O2)]1
Most frequent institutions
- AUGUSTA UNIVERSITY1
- CHILDREN'S RESEARCH INSTITUTE1
- PHOENICIA BIOSCIENCES, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Phase I study of panobinostat in adults with sickle cell disease: novel approach to recruitment and retention1R33HL162681-01 | KUTLAR, ABDULLAHPACE, BETTY SUE | AUGUSTA UNIVERSITY, GA | $782,126 | ZHL1 |
| 2020 | Development of a Clinical Hemoglobin Modulator1R33HL147845-01A1 · under PAR-18-684 | FALLER, DOUGLAS VKUO, KEVINPERRINE, SUSAN PARKSINGER, SYLVIA T | PHOENICIA BIOSCIENCES, INC., MA | $1,733,012 | ZHL1 |
| 2019 | Mesenchymal Stromal Cell Delivery through Cardiopulmonary Bypass in Pediatric Cardiac Surgery1R33HL146394-01 · under PAR-18-684 | BOLLARD, CATHERINE M.ISHIBASHI, NOBUYUKIJONAS, RICHARD A | CHILDREN'S RESEARCH INSTITUTE, DC | $881,207 | ZHL1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.